Final Results of National Institute of Allergy and Infectious Diseases ’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 8, 2020-- The New England Journal of Medicine (NEJM) today published the final results from the National Institute of Allergy and Infectious Diseases’ (NIAID) double-blind,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials